Axa Shares Look Cheap: Should You Buy The Stock

Have you ever looked at a large European insurer and thought the market was still pricing it as if nothing had changed in ten years? That is the feeling I get with Axa right now. The group is no longer the sprawling life-and-savings machine it used to be. It has spent a decade simplifying, selling, buying, and shifting toward shorter-duration property and casualty cover. The shares still sit on a modest multiple. That gap between the story and the price is what makes the name worth a proper look, not a headline glance.

Why Axa Shares Are Back On The Radar

Back in the mid-2010s, most of the profit engine sat in life insurance and long-term savings. Those books live and die with rates, capital rules, and contracts that can last decades. Once you write the policy, you live with it. Regulators know that, so they demand thick capital buffers. That is expensive. It also makes the group harder to value because investors have to model a very long tail of liabilities.

The strategic turn under the current leadership was blunt. Push the mix toward short-tail property and casualty business. That book reprices every year. Capital intensity is lower. Management can steer the portfolio instead of babysitting old promises. I have found that investors often underestimate how much that mix shift changes the quality of earnings, even when the brand on the door stays the same.

The Life Book Was The Problem, Not The Brand

Life and annuity products are not bad in themselves. They can be excellent businesses in the right rate environment. The trouble is duration. A contract written in a low-rate world can sit on the balance sheet like a stone. You cannot simply walk away. That is why the group started carving out large pieces of the old model rather than trying to polish every corner of it.

One of the first decisive steps was the separation of the US life arm. That single move unlocked a large slug of capital and gave management room to shop. Almost immediately, the group went after a major global P&C specialist. The cheque was large, north of fifteen billion dollars. Overnight, Axa jumped into the top tier of worldwide property and casualty underwriters. That is not a tweak. That is a change of centre of gravity.

Once an insurer writes a decades-long life or annuity contract, it lives with that promise even if the economics sour. Short-tail cover can be repriced. That difference is the whole strategy.

At the same time, management kept exiting noisy, volatile corners of insurance and reinsurance. Cost came out. Risk came down. The group stopped trying to be everything to everyone. In my experience, that kind of pruning looks dull in the first few years and then suddenly shows up in the quality of the numbers.

How The Revenue Mix Actually Changed

The top line is smaller than it was a decade ago. That scares some people. It should not, at least not on its own. Before the overhaul, total revenue sat around one hundred billion euros, with roughly half coming from life and health. Net income was close to six billion. Fast forward to the early 2020s and revenue had dropped by about a third, yet profit held up far better than the sales line. That is the point of de-risking. You give up bulk. You keep more of what remains.

Then the underwriting cycle turned. From around 2019, inflation and heavy claims pushed prices higher across global insurance and reinsurance. Insurers had to charge more just to keep pace with the cost of putting things back together. At the same time, higher rates improved the yield on the investment portfolios that sit behind the policies. Two tailwinds at once. Rare, and powerful.

By the 2025 financial year, the combined ratio had compressed to about 90.6 percent, from 99.5 percent in 2020. Anything under 100 percent means the underwriting itself makes money before investment income. That is the cleanest kind of insurance profit. Net income climbed to about 9.8 billion euros on roughly 75 billion of revenue. Of that revenue, around 58 billion came from P&C. The mix the board wanted is now visible in the accounts, not just in slide decks.

Look at that table for a second. Revenue down, profit up over the full arc. That is not magic. It is a less capital-hungry book plus a hard market. The hard market will not last forever. The cleaner book might.

Selling The Asset Manager And Handing Cash Back

The next chapter was the sale of the asset-management arm. The buyer paid about 5.4 billion euros, a rich multiple of earnings at the time. Combined with the acquirer’s platform, the new manager sat on roughly 1.5 trillion euros of assets. Scale matters in that industry. For Axa, the more interesting part was the use of proceeds. Most of the cash went straight back to shareholders through a buyback. That is a different capital culture from the old conglomerate years.

I like that signal. When a group sells a non-core engine and does not immediately hunt for another empire, it tells you management is thinking about per-share value, not just size. Buybacks only help if the stock is cheap and the balance sheet can take it. On both counts, the timing looked sensible.

The New Three-Year Plan Is About Earnings, Not Theatre

In mid-September the group set out its 2027 to 2029 plan. The last plan already asked for mid-to-high single-digit growth. The new one lifts the ambition to 7 to 9 percent compound earnings growth. That is not a moonshot. It is a stretch from a cleaner base. To get there, the company will need a broader European footprint, especially among smaller and mid-sized firms, plus serious cost work.

Analysts talking about the plan put a lot of weight on technology, including AI tools inside claims, pricing, and administration. One house suggested those savings could add about a point of earnings growth a year across the group. A single point does not sound dramatic until you compound it on a business that already throws off cash. Perhaps the most interesting aspect is how unglamorous that is. No new continent. No flashy product launch. Just a tighter machine.

Cash is the other pillar. Management wants about 25 billion euros of cumulative cash from subsidiaries over three years, up from 21 billion in the previous window. A large slice of that is earmarked for investors. Forecasts I have seen put ordinary cash returns around 5.4 billion in 2027 and 5.8 billion in 2028, with the stock offering a dividend yield near 5.8 percent on those numbers. Buybacks from 2024 through 2028 could cut the share count by more than a tenth. Put dividends and repurchases together and the total shareholder yield sits near 7.8 percent in 2027 and 8.4 percent in 2028. That is real money, not a slogan.

• Target earnings growth of 7% to 9% a year through 2029
• Up to several million euros a year in extra cost takeout, with technology doing a lot of the work
• About €25 billion of cumulative subsidiary cash over three years
• Dividend plus buyback yield that can sit in the high single digits
• Share count that could shrink by more than 10% over a multi-year window

What The Valuation Is Actually Saying

On forward earnings, the shares have been changing hands around eight times. On book value, the multiple sits near 1.59. For a large, diversified insurer with a growing P&C engine and a stated cash-return plan, that is not a rich ticket. Markets usually haircut insurers because the cycle can snap. Fair enough. The question is whether this particular haircut is too deep given the shorter duration of the book.

I keep coming back to that point. A long-tail life book is hard to reprice when the world changes. A P&C portfolio turns over. If prices soften, the group can tighten terms at the next renewal. If claims spike in one line, it can walk away from the worst accounts. That flexibility should command a better rating than a closed, decades-long savings book. It does not always get one. Habits in the market die slowly.

Insurers almost always trade at a discount to the wider equity market because losses can arrive in clusters. The debate is not whether the discount exists. It is whether Axa’s discount still matches the business it actually runs today.

Price-to-earnings of eight is the kind of multiple you see when people assume growth will fade and capital returns will slip. Management is telling a different story. Somebody is wrong. That is what makes the stock interesting rather than merely cheap.

The Risks You Cannot Shrug Off

A soft market is the obvious one. When capacity floods in and prices fall, growth can vanish even at a well-run firm. A bad year for catastrophes can punch a hole in the combined ratio and force the board to slow buybacks. Every insurer lives with that weather. Axa is large, which helps on diversification, but size does not cancel a global price war.

Interest rates cut both ways now. The recent lift in portfolio yields helped. A sharp drop would trim investment income just as underwriting margins might already be under pressure. There is also execution risk inside the cost plan. Technology savings look neat on a slide. They are messier in claims departments and local entities spread across Europe and beyond.

Then there is the human factor. Large insurers are political animals. Local management, regulators, unions, and distribution partners all have a vote in practice if not on paper. A 7 to 9 percent earnings path assumes those frictions stay manageable. They might. They might not.

1. Watch the combined ratio each reporting season, not just the headline profit.
2. Track cash remitted from operating units, because that funds the yield story.
3. Listen for language on pricing in commercial lines and specialty books.
4. Measure buyback pace against the original three-year map.
5. Keep an eye on capital ratios after large events, not only after quiet quarters.

None of that is exotic. It is the ordinary hygiene of owning an underwriter. People get bored of it. Then a hurricane season or a liability shock arrives and the bored people remember why the checklist exists.

How Axa Fits A Broader Portfolio

This is not a rocket ship. It is a cash compounder with cyclical skin. That profile can sit well beside growth stocks that pay little and beside bonds that now yield less than they did at the peak of the rate scare. The dividend is meaningful. The buyback can add a second engine if the multiple stays depressed. Together they create a shareholder yield that looks more like an income strategy with optionality than a speculative bet on multiple expansion.

Currency is part of the package. The shares are listed in Paris. A sterling or dollar investor is taking euro exposure whether they notice or not. Some people hedge that. Some treat it as a feature. Either way, pretend it is not there and you will be surprised one year.

I would not build a whole book around a single insurer. Correlation among large European names can rise when the cycle turns. A modest position, sized so a soft market is annoying rather than fatal, feels more honest. That is not timid. That is how you stay in the game long enough for the compounding to matter.

Short-Tail Cover And Why The Cycle Still Matters

Let me linger on the product economics, because this is where a lot of casual commentary goes vague. Property and casualty policies, especially commercial and specialty lines, are designed to be re-underwritten. Terms, deductibles, exclusions, and price can all move at renewal. Health books have their own rhythm, but they are still closer to an annual conversation than a thirty-year annuity.

That agility is why the strategic pivot was worth the disruption. It is also why a hard market feels so good and a soft market feels so fast. When prices are rising, the same underwriting team suddenly looks brilliant. When prices fall, the same team looks ordinary. The skill is staying disciplined in both climates. Easy to say. Hard to do when brokers are shopping every risk and competitors are hungry for volume.

Axa’s scale in P&C and health is an advantage if management uses it to walk away from poorly priced accounts. Scale becomes a trap if the firm starts defending market share at any price. The next three years will tell us which instinct wins. The plan on paper leans toward quality. Markets will test that lean.

Capital Light Is Relative, Not Absolute

People toss around “capital light” as if an insurer can run on fumes. It cannot. Even a short-tail book needs surplus for shocks, model error, and growth. The claim is comparative. Life savings books soak up more capital for longer. P&C recycles capital faster if the combined ratio behaves. That faster recycle is what funds the buybacks.

After the US life separation, the XL-related expansion, and the asset-manager sale, the group is closer to that comparative ideal than it was in 2016. Not perfect. Closer. Investors who still model Axa as a rate-sensitive savings giant are using an old map. Maps go stale. Portfolios that follow them do too.

Simple way to think about the equity story:
  Cleaner mix
  + Hard-market residue
  + Cost takeout
  + Cash returned
  = Higher earnings per share if the cycle does not collapse

That little stack is not a guarantee. It is a framework. If one layer fails, the others have to work harder. If two fail at once, the cheap multiple starts to look fair. That is the adult version of the bull case.

What “Cheap” Does And Does Not Mean

Cheap is a slippery word. A stock can be inexpensive because the future is dull. It can also be inexpensive because the last decade trained investors to ignore the name. Axa has a bit of both in the price. The sector discount is structural. The extra discount, if there is one, comes from leftover complexity in people’s heads.

A forward multiple near eight only looks silly if the 7 to 9 percent earnings path is credible and if cash keeps arriving on schedule. If growth lands at four and buybacks pause after a rough catastrophe year, eight times is not a gift. It is a warning label you ignored. Valuation is a conversation with the future, not a sticker on the past.

I’ve found that the cleanest way to use a name like this is to decide in advance what would make you sell. A sustained combined ratio back above 97 percent with no pricing response. A cut in the cash-return map that is not explained by a one-off event. A return to empire building. Write those down. Otherwise you will negotiate with yourself when the chart looks ugly.

Europe, SMEs, And The Unglamorous Growth Engine

The plan’s growth story is not a dash into a fashionable new region. It is deeper penetration of European small and mid-sized firms. That market is fragmented, relationship driven, and often underserved by giants that prefer jumbo accounts. It is also operationally heavy. You need local product, local claims, and a distribution model that does not treat a ten-person company like a rounding error.

If Axa gets that right, the earnings path becomes less dependent on the peak of the commercial pricing cycle. If it gets it wrong, the 7 to 9 percent target leans too hard on cost cuts and buybacks. Those two levers still matter. They are not a full strategy on their own.

There is a cultural piece here as well. Large French groups can be excellent at industrial logic and clumsy at local agility. The last ten years suggest this management team is more willing to exit and focus than some peers. That is encouraging. It is not proof that SME underwriting across a dozen markets will be smooth.

Buybacks, Dividends, And The Math Of A Shrinking Share Count

A shrinking share count is one of the few corporate actions that can lift earnings per share even when the underlying business is only modestly better. Over a four-to-five-year window, a reduction of more than 10 percent is not trivia. Pair that with a mid-single-digit dividend and you have a total return profile that can work in sideways markets.

The danger is treating the buyback as a permanent law of nature. Boards cancel programmes when capital ratios wobble. They should. Policyholders sit above shareholders in the real hierarchy of an insurer, even if equity investors prefer not to think about that on quiet days. A healthy yield is a privilege earned by surplus capital, not a coupon stamped on the stock forever.

Still, if the cash map is even roughly right, the next couple of years offer an unusual combination: a low earnings multiple and a high cash-return yield. That pairing does not show up every season in large-cap Europe. When it does, it deserves more than a shrug.

A Practical Way To Think About Position Size

If the thesis is “cleaner insurer, decent yield, option on continued discipline,” then size the holding as an income-and-quality sleeve, not as a high-conviction concentrated bet. Reinvest the dividend if you do not need the cash. Let the buyback do some of the compounding in the background. Review after each full-year result against the combined ratio, cash remittance, and tone on pricing.

Would I call it a screaming bargain that must be bought this week? No. Markets can keep a cheap insurer cheap for a long time. Would I call it a name that looks mis-labelled after a decade of work? Yes. That is a quieter conclusion. It is also a more useful one.

Insurance will never be a story stock in the way a software platform can be. Claims arrive. Models fail. Weather does what weather does. The job is to own the underwriters that respond fastest and give the extra cash back instead of decorating the office. On that narrower test, Axa is in a better place than the 2016 version of itself. The share price still seems to remember the old version more clearly than the new one.

So, Should You Buy?

There is no universal yes. It depends on whether you can live with catastrophe volatility and a sector that the market will always distrust a little. If you need explosive growth, look elsewhere. If you want a large, simpler P&C and health platform with a stated plan to grow earnings at 7 to 9 percent and send a high single-digit total yield back to owners, the current multiple gives you a fair starting point.

The short-tail book is the feature that makes the valuation argument possible. Annual repricing will not save the group from a truly brutal market. It does give management a steering wheel that the old life-heavy model did not. After ten years of using that wheel, the accounts look different. The rating has not fully caught up. That gap is the whole case.

Watch the next few reporting seasons with a cold eye. If pricing holds up better than feared and cash arrives as mapped, the cheap label will look earned. If the cycle breaks early, you will be glad you did not bet the house. Either way, this is no longer the tangled savings giant of the last decade. Pricing it as if it were may be the habit the market still needs to break.